Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 5 for:    ocs liver

OCS Liver PROTECT Continued Access Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04186221
Recruitment Status : Recruiting
First Posted : December 4, 2019
Last Update Posted : October 8, 2020
Sponsor:
Information provided by (Responsible Party):
TransMedics

Brief Summary:
Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers.

Condition or disease Intervention/treatment Phase
Liver Transplant Device: OCS Liver System Not Applicable

Detailed Description:

A prospective, single arm, continued access protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers having one or more of the following characteristics:

  1. Donor age equal to or greater than 40 years old, or
  2. Expected cross clamp time of 6 hours or greater, or
  3. Donor after circulatory death (DCD) with age less than or equal to 55 years; or
  4. Steatotic lever >0% and less than or equal to 40% at time of retrieval, based on pre-retrieval histology)

A maximum of 21 sites will enroll up to 184 transplanted liver recipients. The primary effectiveness endpoint will be the incidence of Early Allograft Dysfunction (EAD) or primary non-function.

All recipients will be followed for 24 months from the date of transplantation (some of which will be post-market).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 184 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Prospective, single-arm, continued access protocol
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Continued Access Protocol To Evaluate the Effectiveness of the Portable Organ Care System (OCS) Liver for Preserving and Assessing Donor Livers for Transplantation.
Actual Study Start Date : February 15, 2020
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : March 2022

Arm Intervention/treatment
Experimental: Treatment arm Device: OCS Liver System
OCS Liver System for preserving and assessing donor livers for transplantation




Primary Outcome Measures :
  1. Incidence of EAD or primary non-function [ Time Frame: 7 days ]
    Incidence of early allograft dysfunction or primary non-function of donor liver


Secondary Outcome Measures :
  1. OCS donor liver assessment during perfusion [ Time Frame: During OCS perfusion, on average 4 hours ]
    Collection of liver perfusion parameters while on OCS device

  2. Patient Survival at Day 30 post-transplantation [ Time Frame: 30 days ]
    Survival

  3. Patient Survival at initial hospital discharge post liver transplantation [ Time Frame: 30 days ]
    Survival


Other Outcome Measures:
  1. Length of initial post-transplant ICU stay [ Time Frame: ICU days, on average 5 days ]
    ICU stay

  2. Length of initial post-transplant hospital stay [ Time Frame: Hospital days, on average 10 days ]
    Hospital stay

  3. Evidence of ischemic biliary complications diagnosed at 6 and 12 months post transplant [ Time Frame: 6 and 12 months ]
    Ischemic biliary complications

  4. Extend to reperfusion syndrome as assessed based on the rate of decrease of lactate [ Time Frame: anhepatic phase, 30-40 minutes after hepatic artery and portal vein reperfusion, 90-120 minutes after reperfusion of the transplanted liver ]
    Reperfusion syndrome

  5. Pathology sample score for liver samples [ Time Frame: Procedure (Pre-retrieval, Post-OCS preservation (on average, 4 hours), post reperfusion 90-120 min after reperfusion and prior to abdominal closure) ]
    Pathology sample scoring



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Recipient Inclusion Criteria:

  • Registered primary liver transplant candidate, male or female
  • Age ≥ 18 years
  • Signed (1) written informed consent document and (2) authorization to use and disclose protected health information

Exclusion Criteria:

  • Acute, fulminant liver failure
  • Prior solid organ or bone marrow transplant
  • Chronic use of hemodialysis or diagnosis of chronic renal failure, defined as chronic serum creatinine of > 3 mg/dl for > 2 weeks and/or requiring hemodialysis
  • Multi-organ transplant
  • Ventilator dependent
  • Dependent on > 1 IV inotrope to maintain hemodynamics

Donor Inclusion Criteria

  • Donor age ≥ 40 years, or
  • Expected cross-clamp time ≥ 6 hours, or
  • Donor after circulatory death (DCD) with age ≤ 55 years, or
  • Steatotic liver > 0% and ≤ 40% macrosteatosis at time of retrieval

Donor Exclusion Criteria

  • Living donors
  • Liver intended for split transplants
  • Positive serology (HIV, Hepatitis B surface antigen & Hepatitis C)
  • Presence of moderate or severe traumatic liver injury, or anatomical liver abnormalities that would compromise ex-vivo perfusion of the donor liver (i.e., accessory blood vessels or other anatomy that require surgical repair) and livers with active bleeding (e.g., hematomas)
  • Donor livers with macrosteatosis of > 40% based on retrieval biopsy readout.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04186221


Contacts
Layout table for location contacts
Contact: Kelly Jork 978-494-3918 kjork@transmedics.com
Contact: Kausar Qidwai 978-494-7105 kqidwai@transmedics.com

Locations
Layout table for location information
United States, California
Scripps Recruiting
La Jolla, California, United States, 92037
Contact: Michelle Meyer    858-554-4340    meyer.michelle@scrippshealth.org   
Principal Investigator: Christopher L Marsh, MD         
UCSF Recruiting
San Francisco, California, United States, 94143
Contact: Tyler Lunow-Luke    415-353-8465    tyler.lunow-luke@ucsf.edu   
Principal Investigator: Garrett Roll, MD         
United States, Florida
Tampa General Withdrawn
Tampa, Florida, United States, 33606
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Kerry Crisalli    617-643-4087    kcrisalli@mgh.harvard.edu   
Principal Investigator: James Markmann, MD         
United States, Michigan
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Catherine Crombez    313-916-4596    ccrombe1@hfhs.org   
Principal Investigator: Marwan Abouljoud, MD         
United States, Nebraska
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Patricia Moffatt    402-552-6240    pat.moffatt@unmc.edu   
Principal Investigator: Shaheed Merani, MD         
United States, New York
Montefiore Einstein Center for Transplantation Recruiting
Bronx, New York, United States, 10467
Contact: Omar Alani    347-671-8217    omohamme@montefiore.org   
Principal Investigator: Milan Kinkhabwala, MD         
Mount Sinai Hospital Recruiting
New York, New York, United States, 10029
Contact: Brandy Haydel    212-241-0255    brandy.haydel@mountsinai.org   
Principal Investigator: Sander Florman, MD         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Corey Newsome    614-293-5648    corey.newsome@osumc.edu   
Principal Investigator: Sylvester Black, MD         
United States, Tennessee
Methodist University Hospital Recruiting
Memphis, Tennessee, United States, 38104
Contact: Melissa Morgan    901-478-9184    Melissa.morgan@mlh.org   
Principal Investigator: Cory Eymard, MD         
United States, Texas
University of Texas Southwest Recruiting
Dallas, Texas, United States, 75390
Contact: Emily Carlson    214-648-7609    emily.carlson@utsouthwestern.edu   
Principal Investigator: Malcolm MacConmara, MD         
Houston Methodist Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Darrel Cleere, RN    713-441-6311    DWCLEERE@houstonmethodist.org   
Principal Investigator: Ashish Saharia, MD         
The University of Texas Health Science Center at San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Jillian Woodworth    210-818-9525    woodworthj@uthscsa.edu   
Principal Investigator: Tarunjeet Klair, MD         
United States, Virginia
Virginia Commonwealth University Health System Recruiting
Richmond, Virginia, United States, 23298
Contact: Mary Baldecchi    804-828-7925    mary.baldecchi@vcuhealth.org   
Principal Investigator: Chandra Bhati, MD         
Sponsors and Collaborators
TransMedics
Investigators
Layout table for investigator information
Study Director: Ahmed Elbetanony, MD TransMedics
Layout table for additonal information
Responsible Party: TransMedics
ClinicalTrials.gov Identifier: NCT04186221    
Other Study ID Numbers: OCS-LVR10202019
First Posted: December 4, 2019    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes